Cybin pushes forward with Phase 3 depression trials after posting a narrower loss, while securing a $100M funding program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback